Latest & greatest articles for duloxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on duloxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on duloxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for duloxetine

41. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder Armstrong EP, Malone DC, Erder MH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to compare the cost-effectiveness of two branded treatments for major depressive disorder. The authors concluded that escitalopram was more effective and less costly than duloxetine. The methodology appears to have been appropriate and, on the whole, was clearly and transparently reported. The conclusions

2008 NHS Economic Evaluation Database.

42. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data

Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data Wade A G, Fernandez J L, Francois C, Hansen K, Danchenko N, Despiegel N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of escitalopram and duloxetine in the treatment of major depressive disorder (MDD) in the UK. The authors concluded that, from a UK societal perspective, escitalopram led to a reduction in costs and improved clinical outcomes in comparison

2008 NHS Economic Evaluation Database.

43. An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence

An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence Das Gupta R, Caiado M, Bamber L Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared five different options for the treatment of moderate-to-severe stress urinary incontinence (SUI). The options compared were: current standard treatment in the authors' setting; duloxetine alone as first-line treatment; duloxetine

2006 NHS Economic Evaluation Database.

44. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training

Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

45. Duloxetine for fibromyalgia - horizon scanning review

Duloxetine for fibromyalgia - horizon scanning review Duloxetine for fibromyalgia - horizon scanning review Duloxetine for fibromyalgia - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Duloxetine for fibromyalgia - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005 (...) Authors' objectives This study aims to summarise the currently available evidence on Duloxetine for fibromyalgia Authors' conclusions Duloxetine (Yentreve, Cymbalta, LY 248686) is a dual serotonin and noradrenaline re-uptake inhibitor (SNRI) in phase III trials for the management of the symptoms of fibromyalgia. If successful in licensing it will be the first pharmaceutical licensed for fibromyalgia. Two 12 week randomised, placebo controlled trials in 207 patients and 354 women, found that duloxetine

2005 Health Technology Assessment (HTA) Database.

46. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials

Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

47. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder

Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 NHS Economic Evaluation Database.

48. Cymbalta (Duloxetine Hydrochloride)

Cymbalta (Duloxetine Hydrochloride) Drug Approval Package: Cymbalta (Duloxetine Hydrochloride) NDA #021427 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Cymbalta (Duloxetine Hydrochloride) Capsules Company: Eli Lilly & Co., Inc. Application No.: 021427 Approval Date: 8/03/2004 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) Chemistry Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) Clinical Pharmacology Biopharmaceutics

2004 FDA - Drug Approval Package

49. Duloxetine for major depressive disorder and stress urinary incontinence

Duloxetine for major depressive disorder and stress urinary incontinence Duloxetine for major depressive disorder and stress urinary incontinence Duloxetine for major depressive disorder and stress urinary incontinence Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian (...) Coordinating Office for Health Technology Assessment. Duloxetine for major depressive disorder and stress urinary incontinence. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2004 Authors' objectives To summarize the available information on the use of duloxetine hydrochloride (Trade Mark: Cymbalta) for the treatment of major depressive disorder and stress urinary incontinence in women. Authors' conclusions Duloxetine is another choice in the growing list of marketed

2004 Health Technology Assessment (HTA) Database.